Sunit | Stock Market Kid

Sahajanand Medical Technologies (SMT): From a Vision in Surat to a Potential Billion-Dollar Global MedTech Company. Thanks to @arvind_kothari @niveshaay , had the chance to meet the management and interact with them before ipo at The Dhando Valley. Lets start with the story! In the late 1990s, when India was largely dependent on expensive imported cardiac stents, an entrepreneur from Surat saw an opportunity to change that. Dhirajlal Kotadia, an engineer and entrepreneur who had already built a successful precision-engineering and laser-technology business serving the diamond industry, believed India could manufacture world-class cardiovascular devices at affordable prices. The vision was ambitious: develop life-saving medical technology in India, reduce dependence on imported devices and make advanced cardiac treatment accessible to more patients. That vision led to the creation of Sahajanand Medical Technologies, whose origins go back to 1999 and which was incorporated in 2001. What started with coronary stents has evolved into something much bigger. Over the next 25 years, SMT invested heavily in research, clinical trials, product development and international expansion. Today, the company has: Presence across 77 countries Approximately 25% share of India’s drug-eluting stent market by volume 119 granted patents and 78 pending patent applications 75 clinical studies, including 66 completed Manufacturing capabilities across India and Thailand Products spanning coronary stents, balloons, occluders and transcatheter heart valves The company has also transitioned to its next generation of leadership, with Bhargav Kotadia taking over as CEO in April 2025. But what interests me most is the economics of this 25-year journey. My reconstruction of SMT’s historical filings suggests that the company has spent approximately(min) ₹950 crore cumulatively on R&D and clinical development, with ₹631 crore identifiable across disclosed financial periods. In today’s purchasing-power terms, that historical R&D investment could be worth approximately ₹1,300 crore. Add acquisitions, international distribution, manufacturing infrastructure and the time required to establish clinical credibility, and the barriers to recreating this business become significant. Despite all this investment, SMT currently operates at only around 14% consolidated EBITDA margins. Europe, now its largest market, has only recently reached operating breakeven, while India and the Rest of the World already operate above 20% EBITDA margins. This raises an interesting question. What happens when a company that has spent 25 years developing technology, products and global distribution finally starts monetising those investments at scale? At ₹2,000 crore revenue and 20–25% EBITDA margins, SMT could potentially generate ₹400–500 crore EBITDA, compared with ₹171 crore in FY26. And the company is no longer dependent only on coronary stents. Structural Heart, TAVI, occluders, drug-coated balloons and next-generation devices could provide the next leg of growth. I spent time studying SMT’s RHP, its older DRHPs, acquisition history, R&D spending, product pipeline and global cardiovascular markets. Here is my detailed thesis on why Sahajanand Medical Technologies could become one of India’s most interesting global MedTech businesses. A deep dive into SMT’s business, R&D moat, acquisitions, products, margins and what could change over the next 3–5 years. 1. First, understand the business. SMT is much more than an Indian coronary stent manufacturer. It operates across two major categories: * Vascular Intervention: Coronary stents, balloons and related devices. * Structural Heart: TAVI valves, occluders and other devices. FY26 revenue: ₹1,211 Cr EBITDA: ₹171 Cr EBITDA margin: 14.1% PAT: ₹69 Cr The business is already global, but profitability could be at an inflection point.